Stragen Pharma Group sold to ArchiMed
28 June 2021 – Stragen Pharma Group has been sold to Private equity healthcare specialist, ArchiMed through its EUR 1 billion MED Platform I fund.
Stragen Pharma is based near Geneva, Switzerland and was founded in 1990. It is a developer of hard-to-make, complex generic drugs for the treatment of patients with life-threatening conditions that require comprehensive care and monitoring, usually in intensive care units. Stragen sales of some EUR 70 million in 2020 are growing at a double-digit annual pace. Stragen’s 40 different products are sold in over 60 countries around the world, with a strong European focus.
Walder Wyss advised Stragen Pharma and its shareholders in the transaction. The team was led by Fouad G. Sayegh (Partner, Tax) and Patrick W. Vogel (Partner, Corporate/M&A) and included Yacine Rezki (Associate, Tax), Alexander Sorton (Associate, Corporate/M&A), Hugh Reeves (Managing Associate, IP) and Camille Tistounet (Trainee Lawyer).